PL2057139T3 - Pochodne siarkowodorowe niesteroidowych leków przeciwzapalnych - Google Patents

Pochodne siarkowodorowe niesteroidowych leków przeciwzapalnych

Info

Publication number
PL2057139T3
PL2057139T3 PL07763931T PL07763931T PL2057139T3 PL 2057139 T3 PL2057139 T3 PL 2057139T3 PL 07763931 T PL07763931 T PL 07763931T PL 07763931 T PL07763931 T PL 07763931T PL 2057139 T3 PL2057139 T3 PL 2057139T3
Authority
PL
Poland
Prior art keywords
hydrogen sulfide
steroidal anti
inflammatory drugs
sulfide derivatives
derivatives
Prior art date
Application number
PL07763931T
Other languages
English (en)
Inventor
John L Wallace
Giuseppe Cirino
Vincenzo Santagada
Giuseppe Caliendo
Original Assignee
Antibe Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antibe Holdings Inc filed Critical Antibe Holdings Inc
Publication of PL2057139T3 publication Critical patent/PL2057139T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/48—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
PL07763931T 2006-07-18 2007-07-18 Pochodne siarkowodorowe niesteroidowych leków przeciwzapalnych PL2057139T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80763906P 2006-07-18 2006-07-18
US88718807P 2007-01-30 2007-01-30
PCT/CA2007/001289 WO2008009127A1 (en) 2006-07-18 2007-07-18 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
EP07763931.8A EP2057139B1 (en) 2006-07-18 2007-07-18 Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs

Publications (1)

Publication Number Publication Date
PL2057139T3 true PL2057139T3 (pl) 2014-06-30

Family

ID=38956479

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07763931T PL2057139T3 (pl) 2006-07-18 2007-07-18 Pochodne siarkowodorowe niesteroidowych leków przeciwzapalnych

Country Status (18)

Country Link
US (1) US8314140B2 (pl)
EP (2) EP2057139B1 (pl)
JP (2) JP5408719B2 (pl)
KR (2) KR101495520B1 (pl)
AU (2) AU2007276621B2 (pl)
BR (2) BRPI0714466B8 (pl)
CA (2) CA2658433C (pl)
DK (1) DK2057139T3 (pl)
ES (1) ES2437223T3 (pl)
HK (2) HK1131125A1 (pl)
IL (2) IL196228A0 (pl)
MX (2) MX2009000749A (pl)
NO (2) NO342083B1 (pl)
NZ (1) NZ573996A (pl)
PL (1) PL2057139T3 (pl)
PT (1) PT2057139E (pl)
RU (2) RU2468019C2 (pl)
WO (2) WO2008009127A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741359B2 (en) * 2005-05-27 2010-06-22 Antibe Therapeutics Inc. Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
KR101495520B1 (ko) * 2006-07-18 2015-02-26 안티브 홀딩스 인크. 약제의 4-하이드록시티오벤즈아미드 유도체
ITMI20080382A1 (it) * 2008-03-07 2009-09-08 Ctg Pharma S R L Composizioni farmaceutiche oculari
ITMI20081167A1 (it) * 2008-06-26 2009-12-27 Ctg Pharma S R L Composizioni farmaceutiche per il trattamento di malattie neurodegenerative
US8541396B2 (en) 2009-04-24 2013-09-24 National University Of Singapore Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent
WO2011053597A1 (en) * 2009-10-26 2011-05-05 The University Of Memphis Research Foundation Pipemidic acid derivative autotaxin inhibitors
WO2014015047A1 (en) * 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
CA3024556A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
JP2021066660A (ja) * 2018-02-09 2021-04-30 アピオン・ジャパン有限会社 Ｔｉｒａｐ阻害剤
WO2022115952A1 (en) * 2020-12-03 2022-06-09 Antibe Therapeutics Inc. [1-(4-chloro-benzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-acetic acid 4-thiocarbamoyl-phenyl ester for the treatment of a viral infection
WO2023159296A1 (en) * 2022-02-28 2023-08-31 Antibe Therapeutics Inc. 4-thiocarbamoylphenyl 2-(4-oxophenyl)-phenyl propanoate for the treatment of pain associated with urologic chronic pelvic pain syndrome
GR1010438B (el) * 2022-03-21 2023-04-06 UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", Φαρμακευτικες ενωσεις που βασιζονται στο συνδυασμο ενος ανταγωνιστη της ισταμινης και ενος δοτη υδροθειου για χρηση στην αντιμετωπιση του κνησμου

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE612252A (pl) 1961-01-05
US4170654A (en) 1976-02-13 1979-10-09 Merck & Co., Inc. Antihypertensive compositions containing N-heterocyclicalanines and α-
US4112095A (en) 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US5663416A (en) 1990-05-22 1997-09-02 Cortech Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
US5214191A (en) 1990-05-22 1993-05-25 Cortech, Inc. Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase
EP0937711A1 (de) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6429223B1 (en) 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
US7638513B2 (en) 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders
EP1630164A1 (en) * 2004-08-31 2006-03-01 Expotrend Company SA Pyrazolopyrimidinones as phosphodiesterase inhibitors
EP1645288A1 (en) * 2004-10-07 2006-04-12 CTG Pharma S.r.l. New nuclear transcription factors regulators
CN2757375Y (zh) * 2004-11-25 2006-02-08 富士康(昆山)电脑接插件有限公司 电子卡连接器
JP2008534475A (ja) 2005-03-24 2008-08-28 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ６−チアミド置換されたベンゾイミダゾール
ITMI20050680A1 (it) * 2005-04-18 2006-10-19 Ctg Pharma S R L Nuovi composti anti-infiammatori
US7498355B2 (en) * 2005-05-27 2009-03-03 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
US20060270635A1 (en) * 2005-05-27 2006-11-30 Wallace John L Derivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
KR101495520B1 (ko) * 2006-07-18 2015-02-26 안티브 홀딩스 인크. 약제의 4-하이드록시티오벤즈아미드 유도체

Also Published As

Publication number Publication date
NO20090764L (no) 2009-04-16
CA2658429A1 (en) 2008-01-24
JP5529534B2 (ja) 2014-06-25
US8314140B2 (en) 2012-11-20
CA2658433A1 (en) 2008-01-24
BRPI0714330A2 (pt) 2013-05-07
CA2658433C (en) 2015-04-28
IL196228A0 (en) 2009-09-22
JP2009543813A (ja) 2009-12-10
WO2008009118A1 (en) 2008-01-24
EP2057139A1 (en) 2009-05-13
NZ573996A (en) 2012-03-30
JP5408719B2 (ja) 2014-02-05
PT2057139E (pt) 2013-12-05
AU2007276621A1 (en) 2008-01-24
KR101495520B1 (ko) 2015-02-26
MX2009000750A (es) 2009-01-30
US20090306412A1 (en) 2009-12-10
KR20090036115A (ko) 2009-04-13
RU2468019C2 (ru) 2012-11-27
AU2007276621B2 (en) 2013-08-01
EP2057139A4 (en) 2010-09-15
HK1131125A1 (en) 2010-01-15
WO2008009127A1 (en) 2008-01-24
DK2057139T3 (da) 2013-11-18
EP2057139B1 (en) 2013-09-04
ES2437223T3 (es) 2014-01-09
NO20090763L (no) 2009-04-03
JP2009543811A (ja) 2009-12-10
KR20090040428A (ko) 2009-04-24
BRPI0714466A2 (pt) 2013-05-14
IL196229A (en) 2016-04-21
EP2041108B1 (en) 2014-05-21
KR101450653B1 (ko) 2014-10-14
IL196229A0 (en) 2009-09-22
RU2465271C2 (ru) 2012-10-27
RU2009105491A (ru) 2010-08-27
BRPI0714466B8 (pt) 2021-05-25
EP2041108A1 (en) 2009-04-01
MX2009000749A (es) 2009-01-30
HK1131973A1 (en) 2010-02-12
AU2007276679A1 (en) 2008-01-24
NO342083B1 (no) 2018-03-19
AU2007276679B2 (en) 2013-05-30
RU2009105498A (ru) 2010-08-27
EP2041108A4 (en) 2010-12-29
BRPI0714466B1 (pt) 2020-09-24

Similar Documents

Publication Publication Date Title
IL196229A0 (en) Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
HK1147912A1 (en) Anti-inflammatory compounds and uses thereof
HK1204548A1 (en) Uses of dpp iv inhibitors dpp iv
IL200603A0 (en) Inhibitors of the hedgehog pathway
AP2009005011A0 (en) Metabolites of (thio)-carbamoyl-cyclohexane derivatives
IL201611A0 (en) Lipoic acid derivatives
CR10562A (es) Nuevos derivados de piridazina
AP2627A (en) New form of administration of racecadotril
ZA200900422B (en) Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs
GB0604899D0 (en) Derivatives of 18-glycyrrhetinic acid
ZA200709830B (en) Synergistic combinations of non-steroidal anti-inflammatory drugs with alpha-delta-ligands
ZA200905468B (en) Therapeutical uses of eslicarbazepine
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
HUP0700755A2 (en) Pharmaceutical compositions containing capsaicionoid and non-steroidal anti-inflammatory drug
GB0618363D0 (en) Improved use of anti-inflammatory glucocorticosteroids
ZA200906023B (en) Inhibitors of the hedgehog pathway
TWM292045U (en) Improved structure of lamp